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Background: Data on Candida bloodstream infections in pediatric patients 
in Europe are limited. We performed a retrospective multicenter European 
study of the epidemiology and outcome of neonatal and pediatric candi-
demia.
Material and Methods: All first positive blood cultures from patients ≤ 18 
years of age with candidemia were registered. Patients’ demographic and 
clinical characteristics and causative Candida species were collected and 
analyzed. Regression analysis was used to identify factors independently 
associated with mortality.
Results: One thousand three hundred ninety-five episodes of candidemia 
(57.8% male) were reported from 23 hospitals in 10 European countries. Of 
the 1395 episodes, 36.4% occurred in neonates (≤ 44 weeks postmenstrual 
age), 13.8% in infants (> 44 weeks postmenstrual age to 1 year) and 49.8% in 
children and adolescents. Candida albicans (52.5%) and Candida parapsilo-
sis (28%) were the predominant species. A higher proportion of candidemia 
caused by C. albicans was observed among neonatal patients (60.2%) with 
highest rates of C. parapsilosis seen among infants (42%). Children admitted 
to hematology-oncology wards presented the highest rates of non-albicans 
Candida species. Candidemia because of C. albicans was more frequent than 
non-albicans Candida in Northern versus Southern Europe (odds ratio, 2.3; 
95% confidence interval, 1.8–2.9; P < 0.001). The all-cause mortality at 30 
days was 14.4%. All-cause mortality was higher among patients admitted to 
the neonatal or pediatric intensive care units than other wards. Over time, no 
significant changes in species distribution were observed.
Conclusions: This first multicenter European study shows unique charac-
teristics of the epidemiology of pediatric candidemia. The insights obtained 
from this study will be useful to guide clinical management and antifungal 
stewardship.
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Bloodstream infections caused by Candida spp. remain a world-wide cause of substantial in-hospital morbidity and mortality 
and are associated with an increased financial burden.1–5 A propen-
sity analysis conducted in the US revealed that candidemia is asso-
ciated with a mean increase in hospitalization of 21 days, a 10% 
increase in mortality and almost 92,000 US dollars excess per case 
in pediatric inpatient hospital costs.1 Data have additionally shown 
that the epidemiology of candidemia differs significantly among 
pediatric and adult populations, especially in terms of Candida 
species distribution, underlying conditions, risk factors and out-
comes.5–12 Most large prospectively designed epidemiology stud-
ies have excluded pediatric patients. Therefore, detailed knowledge 
of the epidemiology of Candida species among pediatric groups is 
limited. Apart from a few single-center10,13–16 or single country11,17–24 
epidemiologic studies, only one large international pediatric multi-
institutional study has been conducted.6
European multicenter pediatric data have not been collected. 
The European Pediatric Mycology Network (http://www.penta-id.
org/antimicrobials/epmyn/) aims to address this research gap and to 
increase knowledge on the epidemiology of invasive fungal disease 
in neonates and children across Europe. The EUROCANDY study 
is an initiative of the European Pediatric Mycology Network in 
partnership with the Penta network (http://www.penta-id.org) with 
the main objective to characterize the current fungal and clinical 
epidemiology of candidemia among hospitalized neonates, chil-
dren and adolescents across Europe during an extended time.
MATERIAL AND METHODS
Study Design
We conducted a retrospective multicenter study of pediatric 
candidemia (≤ 18 years of age) diagnosed between January 2005 
and December 2015. European centers were approached based on 
their previous participation in Penta clinical studies, hospital char-
acteristics and interest in participating. Individual ethics approval 
was obtained at each site if required by institutional and/or national 
regulations.
A secure web-based data collection tool was developed for 
standardized collection of the data using the Research Electronic 
Data Capture (REDCap) platform (http://www.project-redcap.org), 
with data stored in a secure server located at Penta Foundation offices 
in Padua, Italy. Investigators entered data online or on printed data 
entry forms for off-line data collection initially, followed by entry 
into the web-based system. All data were anonymized, with each 
center assigned a unique Penta center identification number and 
each isolate submitted by each center assigned a unique, consecu-
tive EUROCANDY Isolate ID number within the EUROCANDY 
individual candidemia isolate database. These codes were used to 
link hospital and isolate data. Centers with < 10 candidemia entries 
in the REDCap database were excluded from analysis.
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Data Definition and Data Collection
The secure web-based REDCap database tool enabled the 
standardized collection of the following data: hospital and indi-
vidual admission ward characteristics, annual hospital ward admis-
sions, demographics, clinical characteristics, causative Candida 
species and clinical outcome at day 30. The study period was 
divided into 2 time periods (2005–2010 and 2011–2015, respec-
tively) to allow for the analysis of trends over time.
The study population was stratified according to age and 
ward admitted to. Patients were stratified according to age in the 
following age groups: neonates (postmenstrual age ≤ 44 weeks), 
infants (postmenstrual age > 44 weeks to 1 year) and children and 
adolescents (> 1 year to < 18 years of age).
The classification of pediatric wards included general pedi-
atric ward, pediatric intensive care unit (PICU), neonatal intensive 
care unit (NICU), pediatric hematology-oncology ward (including 
bone marrow transplant unit), pediatric surgery ward, other ICUs 
and other designated pediatric wards (eg, pediatric neurology, pedi-
atric gastroenterology).
All first positive blood cultures (BC) from patients ≤ 18 
years of age with candidemia were included, while any BC from the 
same patient positive for the same Candida species within 30 days 
after the first positive BC was not included. Polyfungal candidemia 
was defined as two or more Candida species present in the same 
BC. BCs with a different Candida species independent of the time 
interval to the first positive BC were included as a new episode. A 
new BC with the same Candida species after an interval of 30 days 
was regarded as a separate candidemia episode and included as 
such in the database. Information with respect to negative follow-
up BC was not collected, and no differentiation was made between 
a relapse or reinfection.
Statistical Analysis
Demographic, clinical and outcome variables were summa-
rized using frequency, percentage, median and first to third interquar-
tile range (IQR). Categorical variables were compared using the χ2 
or Fisher exact test and continuous variables by the Mann-Whitney 
U test. A 2-sided P < 0.05 was considered significant. Differences 
between the qualitative variables in 2 or more groups were analyzed 
by χ2 test in univariate analysis. Binary regression analysis was used 
to identify factors that were significantly associated with mortality. 
Clinically relevant indices in the univariate analysis (P < 0.1) were 
included in a multivariate regression analysis. A multivariable model 
was identified using backward stepwise variable selection methods. 
Statistical analysis was conducted using SPSS (IBM SPSS Statistical 
package for sciences version 23.0, IBM SPSS Inc., New York).
RESULTS
Patient Enrollment
Over the 11-year study period (2005–2015), 1395 pediatric 
candidemia episodes from 23 participating European centers from 
10 countries [Belgium (n = 1), Denmark (n = 2), Germany (n = 
3), Greece (n = 2), Italy (n = 4), the Netherlands (n = 2), Norway 
(n = 1), Serbia (n = 1), Spain (n = 3), United Kingdom (n = 4)] 
were included. Four centers reported < 10 candidemias and were 
excluded from analysis. A total of 59.1% (n = 824) were reported 
from Northern European countries (defined as the United King-
dom, the Netherlands, Belgium, Germany, Denmark and Norway). 
The median number of candidemia episodes entered per country 
was 107 (range: 40–401; IQR: 108). There was no significant dif-
ference between the mean number of episodes per country and 
geographic area of the centers [Northern vs. Southern European 
countries, 137.5 vs. 142.7 (mean) episodes per country (P = 0.9)].
The median number of episodes entered per year was 125 
(range: 95–166; IQR: 31). Between the 2 study periods (2005–2010 
and 2011–2015), there was no significant difference in the median 
number of candidemias reported (first-period median number 125 
vs. second period 121 episodes per year).
Demographic Characteristics
The demographic characteristics of the total cohort are 
shown in Table 1. The median age was 38 months (range: 1–216; 
IQR: 95) with a slight predominance of male sex (57.8%). The 
distribution of episodes in the age categories was as follows: 507 
episodes (36.4%) in neonates, 193 episodes (13.8%) in infants and 
695 episodes (49.8%) in children.
For the neonatal patients, the median gestational age was 
27 weeks (range: 22–42 weeks; IQR: 10) with a median postnatal 
age of 13.5 days (range: 1–127; IQR: 16). For the infant group, 
the median age was 6 months (range: 2–12; IQR: 6), while for the 
pediatric group, the median age was 4.5 years (range: 1.2–18; IQR: 
5.7).
The majority of the patients were admitted to either the 
NICU, PICU, general pediatric or hematology-oncology unit, with 
almost one-third being admitted to the NICU (Table 1).
Candida Species Distribution
Candida albicans was isolated in half of the candidemia 
episodes (52.6%; n = 734), followed by C. parapsilosis (28.1%; 
n = 392). Candida tropicalis, Candida glabrata and Candida kru-
sei were isolated in 4.4%, 3.5% and 2.2% of the episodes, respec-
tively. Nine episodes of candidemia were caused by more than one 
Candida species (0.7%). C. albicans was shown to be the leading 
species causing candidemia independently of the ward type, with 
C. parapsilosis being second to C. albicans (Table 2). A higher 
TABLE 1. Demographics of Neonatal and Pediatric 
Patients With Candidemia During the Study Period 
(2005–2015)
Demographic Characteristics
Total Patient  
Population  
(N = 1395)
Median age in months (range, IQR) 38 (1–216; 95)
Gender male, n (%) 806 (57.8)
Neonatal patients (≤ 44 wk PMA) N = 507
  Median GA in weeks (range, IQR) 27 (22–42; 10)
  Median postnatal age in days (range, IQR) 13.5 (1–127; 16)
  Male gender, n (%) 297 (58.7)
Infants (> 44 wk PMA—1 y) N = 193
  Median age in months (range, IQR) 6 (2–12; 6)
  Male gender, n (%) 109 (56.5)
Children > 1 year N = 695
  Median age in months (range, IQR) 54.5  
(12–216; 102.3)
  Male gender, n (%) 400 (57.6)
Ward type of admission
  Neonatal ICU 422 (30.3%)
  Pediatric ICU 258 (18.4%)
  General Pediatric Ward 238 (17.1%)
  Pediatric Hematology-Oncology Ward* 236 (16.9%)
  Pediatric surgery 106 (7.6%)
  Surgical ICU 36 (2.6%)
  Other† 99 (7.1%)
*Including bone marrow transplant units.
†Including maternity unit, (semi)-intensive care unit, pediatric neurosurgery, 
pediatric endocrinology and metabolic diseases; pediatric neurology, pediatric gastroen-
terology, pediatric infectious diseases and immunology, pediatric nephrology, pediatric 
cardiology, pediatric emergency unit.
GA indicates gestational age.
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proportion of candidemia caused by non-albicans Candida species 
was reported in patients admitted to pediatric hematology-oncol-
ogy wards (60.2%) and other designated pediatrics wards (59.6%) 
(Table 2).
A variation in the distribution of C. albicans was observed 
according to the age of the patients, with higher proportion among 
neonatal patients (60.2%) versus the other 2 age groups (48.7% and 
48.2%). Highest rates of C. parapsilosis were present among infants 
(42%), with clearly less candidemias caused by C. parapsilosis in 
neonates (26%) and children (25.8%) (P < 0.05; 95% confidence 
interval, 0.23–0.36). Focusing on individual patient ward popula-
tions, the distribution of C. albicans versus non-albicans Candida 
candidemia in the NICU setting was different between the 2 periods 
(Table 3). A significant difference in the number of C. parapsilosis 
infections was observed between Northern and Southern European 
countries (16.4% vs. 35.7%; P < 0.001). An increase in the propor-
tion of C. albicans versus C. parapsilosis candidemia episodes in 
the NICUs was observed over time [55.5% (2005–2010) to 65.5% 
(2011–2015); P = 0.03].
The proportion of C. albicans versus non-albicans Candida 
species causing candidemia was different between Northern and 
Southern European countries with higher proportions of C. albi-
cans reported in the Northern countries (58.6% vs. 44%; P = 0.001) 
(Table 4). No differences were observed in the relative number of 
candidemia episodes caused by C. albicans (51.7% vs. 53.7%) and 
non-albicans Candida (48.3% vs. 46.3%) between the 2 periods 
(2005–2010 vs. 2011–2015) (Table 4).
Outcome
All-cause mortality at 30 days was 14.4% (n = 201), with 
non-significant differences between neonates and infants com-
pared with older children (18.2% and 14.5% vs. 11.5%, respec-
tively, P > 0.05). Similar mortality rates were observed for C. 
albicans (13.6%) and C. parapsilosis (12.7%) candidemia, while 
higher mortality rates were observed for C. tropicalis and C. krusei 
(21.3% and 19.3%, respectively) (Table 4). Higher mortality rates 
were reported among patients admitted to the PICU (27.8%, P < 
0.001) and NICU (18.3%, P = 0.01). Lower rates were found for 
patients admitted to general and other pediatric wards (4.7% and 
5.8%, respectively) and pediatric surgical wards (1.8%). A higher 
all-cause mortality rate at 30 days was observed for NICU patients 
(18.3%; 77/422) versus non-NICU patients 12.7% (124/973). The 
mortality rates among NICU patients increased, although not sig-
nificantly, between 2005–2010 and 2011–2015, 35/229 (15.2%) 
and 41/193 (21.7%), respectively (P = 0.127). Higher mortality 
rates among NICU patients were reported when infected with C. 
krusei, other rare species or polycandidal infections, but patient 
numbers were low (Table 3). Remarkably, all-cause mortality was 
higher in the second period of the study, 17.1% versus 12.2% in the 
first period (P = 0.05).
Multivariate Analysis
In the multivariate analysis, the risk of all-cause mortality 
at 30 days was higher for patients admitted to the NICU, PICU and 
pediatric hematology-oncology units (Table 5).
When adjusted for confounding factors as age and type of 
ward admitted to, mortality was lower in the first period (2005–
2010) compared with the second period (2011–2015) (P = 0.05), 
the odds of isolating C. albicans being the cause of candidemia 
was 2.3 times more likely in Northern Europe (P < 0.001), and the 
odds of isolating C. parapsilosis was 2.7 times higher in Southern 
Europe (P < 0.001). As this finding is driven by the significantly 
different distribution between those 2 species observed among 
patients admitted to the NICU, we analyzed the use of neonatal 
antifungal prophylaxis. The use of neonatal antifungal prophylaxis 
overall (median number of years/center) did not differ between 
the 2 regions, but some remarkable differences were noted. Either 
nystatin or fluconazole (both in 50%) was prescribed in the north-
ern countries, while in southern countries only fluconazole was 
prescribed. The median numbers of years in which fluconazole 
prophylaxis was used over the study period was 1.9 y/center (range: 
0–11) and 3.9 y/center (range: 0–9 y) for Northern and Southern 
Europe countries, respectively. The number of centers prescribing 
routinely neonatal fluconazole prophylaxis increased from 1 center 
in 2005 to 6 centers in 2015.
DISCUSSION
To the best of our knowledge, this is the largest European 
multicenter epidemiologic study on candidemia in neonatal and 
pediatric patients, including 23 sites from 10 different European 
countries. Among 1395 candidemia episodes included in the 
EUROCANDY study, C. albicans prevailed followed by C. par-
apsilosis. The distribution of C. albicans versus non-albicans Can-
dida species did not differ significantly among the 2 study periods 
(2005–2010 vs. 2011–2015). Comparing the overall distribution 
of Candida isolates causing candidemia between Northern and 
Southern European centers, a significantly higher proportion of C. 
albicans was noted in the Northern countries. Among the different 
TABLE 2. Distribution of Candida Species Causing Neonatal and Pediatric Candidemia in Specific Wards Where the 























Surgical ICU,  
N = 36
C. albicans 734 (52.5%) 254 (60.1%) 129 (50.5%) 131 (55%) 94 (39.8%) 60 (56%) 40 (40.4%) 26 (72.2%)
C. parapsilosis 392 (28.1%) 117 (27.7%) 79 (31%) 56 (23.5%) 68 (28.8%) 25 (23.6%) 36 (36.3%) 10 (27.8%)
C. tropicalis 61 (4.4%) 12 (2.8%) 15 (5.9%) 10 (4.2%) 14 (5.9%) 4 (3.8%) 6 (6%) 0
C. glabrata 49 (3.5%) 12 (2.8%) 6 (2.3%) 8 (3.3%) 11 (4.6%) 5 (4.7%) 4 (4%) 0
C. krusei 31 (2.2%) 3 (0.7%) 4 (1.6%) 8 (3.3%) 13 (5.5%) 0 1 (1%) 0
Rare/other species† 104 (7.5%) 17 (4.0%) 19 (7.4%) 23 (9.6%) 36 (15.2%) 1 (0.9%) 8 (7.8%) 0
Mixed species‡ 9 (0.7%) 3 (0.7%) 3 (1.2%) 2 (0.8%) 0 1 (0.9%) 2 (2%) 0
Unidentified species 15 (1%) 4 (0.9%) 0 0 0 10 (9.4%) 1 (1%) 0
*Including maternity unit, (semi)-intensive care unit, pediatric neurosurgery, pediatric endocrinology and metabolic diseases; pediatric neurology, pediatric gastroenterology, 
pediatric infectious diseases and immunology, pediatric nephrology, pediatric cardiology, pediatric emergency unit.
†Including C. dubliniensis; C. pulcherrima; C. blankii; C. famata; C. guilliermondii; C. lusitaniae; C. magnolia; C. orthopsilosis; C. zeylanoides; and unidentified Candida species.
‡Mixed Candida infections: C. albicans and C. dubliniensis (n = 1); C. albicans and C. krusei (n = 1); C. albicans and C. lusitaniae (n = 1); C. albicans and C. parapsilosis (n = 2); 
C. albicans and C. pulcherrima (n = 1); C. albicans and C. tropicalis (n = 1); C. glabrata and C. parapsilosis (n = 1); C. parapsilosis and C. tropicalis (n = 1).
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
The Pediatric Infectious Disease Journal • Volume 39, Number 2, February 2020 Pediatric Candidemia in Europe
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.pidj.com | 117
pediatric wards, children admitted to hematology-oncology wards 
presented the highest rates of non-albicans Candida species. A 
higher all-cause mortality was observed for NICU patients than for 
non-NICU patients.
Previously published studies have tried to elucidate the con-
temporary epidemiology of Candida infections over time among 
different pediatric groups and different geographic regions [1, 
6, 9–16, 20–24]. The largest multinational study so far was per-
formed by the International Pediatric Fungal Network (IPFN) for 
2007–2011.6 The results of this study, encompassing predominantly 
centers in the United States (20 United States, 7 European and 3 
other international centers), showed that among 221 patients, non-
albicans Candida species were the predominant cause of invasive 
candidiasis (56%).6 More specifically, focusing on the causative 
species identified from invasive candidiasis in the non-neonatal 
pediatric population (201 isolates), C. albicans was isolated in 44% 
followed by C. parapsilosis in 22%.6 These results are compara-
ble with respect to the non-neonatal pediatric patients (n = 973) 
in our study, where C. albicans was isolated in 49% and C. par-
apsilosis in 28% of the candidemia episodes. Comparison of the 
etiology of neonatal candidemia between the 2 studies is challeng-
ing as only 25 neonates were included in the IPFN study. A more 
recently published surveillance study in the United States (period 
2009–2015) revealed that among 307 pediatric candidemia cases, 
C. albicans prevailed in neonates (68%) and was the single most 
common species found in infants and older children,8 which is very 
similar to our findings. Single country studies have shown country-
specific differences with Slovakia, Turkey, Norway, Denmark and 
the United Kingdom19,21,23,24 showing lower incidences of C. parap-
silosis (10%–31%) in neonates and children, compared with Spain, 
Australia and Latin America (26%–63%).11,17,20
We observed a higher incidence of C. parapsilosis (42%) 
among infants, while for neonates only 28% of candidemias were 
caused by this species. The predominance of C. parapsilosis in 
this specific age group has been previously reported in Spain, with 
63.4% of candidemia in infants being caused by C. parapsilosis.17 
A prospective pediatric study (302 patients) from Latin America 
showed a slightly higher incidence of C. parapsilosis in neonatal 
patients compared with non-neonatal pediatric patients (36% vs. 
26%).11 A prospective study performed in Australia showed high 
incidences for C. parapsilosis candidemia in both the neonatal and 
non-neonatal pediatric patients, 42% and 38%, respectively.20 A 
pediatric surveillance study performed in England and Wales, age-
specific Candida species distribution causing bloodstream infec-
tions was reported.21 In this large study, encompassing 706 neo-
nates and infants < 1 year of age, C. parapsilosis caused 23% of 
the neonatal candidemias and 16% of the candidemias in infants.21 
These differences among the neonatal and pediatric groups might 
reflect different clinical practices and interventions among different 
pediatric age groups. In addition, we may have been able to observe 
the higher prevalence of C. parapsilosis in infants due to the high 
number of pediatric patients included, enabling us to differentiate 
in greater detail age-specific differences.
Our study showed that the rate of C. albicans as cause of 
candidemia was significantly higher in Northern European cent-
ers, while the relative frequencies of C. parapsilosis and C. tropi-
calis candidemia were significantly higher in Southern ones. This 
results from the significant difference in species distribution of 
those 2 species among NICU patients between the 2 geographic 
areas. Neonatal fluconazole prophylaxis was significantly higher 
in Southern European centers compared with Northern ones, but 
whether this is driving the observed differences remains unclear. 
Fluconazole prophylaxis in adult patients has been associated with 
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C. parapsilosis infections have been reported.25 A single country 
multicenter cohort study among 423 extreme low birth weight neo-
nates showed fluconazole prophylaxis increased the incidence of 
infections caused by fluconazole-resistant C. parapsilosis (0% vs. 
41.7%).26 A study to analyze the susceptibility profiles of the Can-
dida isolates reported in this study is currently being undertaken.
Few previously published candidemia surveillance studies 
have shown that irrespective of age, C. albicans remains the most 
important causative agent of candidemia among Northern Euro-
pean countries.18 A higher incidence of C. parapsilosis candidemia 
in South-Europe, Mediterranean countries and Latin America has 
been observed in several population- and hospital-based studies 
(reviewed in 27). These observations are of high clinical impor-
tance and need to be further studied in association with possible 
differences in the health care system practices across Europe, as 
well as the local/national antimicrobial/antifungal stewardship 
programs.
The all-cause mortality rate at 30 days in our study was 
14.4%, which is comparable to the pediatric studies performed in 
the United States and the United Kingdom8,21 and slightly lower 
compared with the rates reported in the IPFN multicenter study.6 
In contrast, mortality rates for neonatal and pediatric candidemia 
were much higher in the study performed in Latin America, includ-
ing 302 patients.18 An explanation for this may lie in the fact that 
in this study, 12.3% of the patients did not receive any antifun-
gal treatment.18 In line with our results, 3 previous studies also 
showed a higher mortality rate among neonates compared with 
older infants and children.6,11,20 As the majority of the neonates are 
prematurely born and admitted to a NICU, the overall severity of 
disease is most likely the explanation for this. The same holds true 
for children admitted to the PICU and developing candidemia with 
a less favorable outcome compared with children admitted to non-
ICU units,16 although not every study has shown this trend.22 The 
higher mortality rate among neonates in the second time period of 
our study is of concern. Part of the explanation may be sought in 
the progress in advanced critical care medicine allowing extremely 
premature infants to survive. The risk for non-survival in our cohort 
was almost 2 times higher for candidemia due to rare Candida 
species compared with C. albicans candidemia. This observation 
needs to be further evaluated in association with other potentially 
relevant factors such as initial treatment prescribed and the differ-
ences in virulence and/or antifungal susceptibility profiles of C. 
albicans versus more rare Candida species.
Certain limitations of our EUROCANDY study need to be 
addressed. First, a selection bias is possible since the retrospective 
design of the study cannot ensure the complete capture of all candi-
demia episodes at each participating center. We aimed to eliminate 
the risk of having a “non-representative European sample” of can-
didemia episodes over the defined time period by excluding centers 
with < 10 candidemia entries or centers located outside Europe. In 
addition, the study population consisted of a heterogenic group of 
pediatric patients and the stratification approach was based on age 
and ward type on admission, both indicating indirectly the underly-
ing conditions rendering them at risk to develop candidemia. Spe-
cific neonatal risk factors as gestational age and birth weight were 
collected, but other specific known risk factors were not obtained 
as this was technically not feasible. Finally, candidemia-attribut-
able mortality data was not available. However, the large number 
of episodes and the broad representation of European centers and 
length of time allowed us to draw important conclusions. Second, 
each center participating in the EUROCANDY study contributed 
differently to the results of the study in term of number of inclu-
sions. Although we aimed to collect the total admissions rates of the 
specific pediatric wards over the study period, relatively few centers 
were able to provide these denominators, which precluded the cal-
culation of incidence rates per center. Future studies are needed to 
capture the incidence rates of pediatric candidemia, the antifungal 
susceptibilities of the Candida isolates, the antifungal prophylaxis 
regimens used and their influence on local/national fungal epide-
miology, as well as the existing pediatric antifungal stewardship 
programs across Europe.
The presented results have provided us with an extended 
insight in the clinical and fungal epidemiology of candidemia in neo-
nates and children among geographically different areas in Europe 













N = 619 P Value* Mortality P Value
C. albicans 483 (58.6%) 250 (44%) 0.001 401 (51.7%) 331 (53.4%) 0.77 100 (13.6%) 0.47†
Candida non-albicans species
  C. parapsilosis 173 (21%) 219 (38.4%) 0.001 238 (30.7%) 154 (25%) 0.019 50 (12.7%) 0.67‡
  C. tropicalis 28 (3.4%) 33 (5.8%)  30 (3.8%) 31 (5%)  13 (21.3%)  
  C. krusei 27 (3.2%) 4 (0.7%)  17 (2.1%) 14 (2.3%)  6 (19.3%)  
  C. glabrata 39 (4.7%) 10 (1.8%)  25 (3.2%) 24 (3.9%)  7 (14.2%)  
*P values for the comparison of C. albicans and C. parapsilosis candidemia in Southern vs. Northern Europe and study period (first vs second period).
†P value for the comparison of mortality due to C. albicans versus non-albicans Candida candidemia.
‡P value for the comparison of mortality due to C. albicans versus C. parapsilosis candidemia.
TABLE 5. Multivariate Predictors of Mortality and 
Species Distribution for the EUROCANDY Cohort
Variables P Value OR 95% CI
Significant predictors for mortality
  PICU admission < 0.001 8.325 4.25–16.27
  NICU admission < 0.001 4.67 2.4–9.08
  Pediatric hematology-oncol-
ogy ward admission
0.004 2.853 1.38–5.86
  2005–2010 (vs. 2011–2015) 0.05 0.64 0.467–0.877
Significant predictors for  
C. albicans candidemia
  Northern Europe < 0.001 2.31 1.825–2.94
  NICU admission 0.03 1.67 1.19–2.35
  Pediatric hematology- 
oncology ward admission
0.001 0.526 0.363–0.763
  Other pediatric ward  
admission
0.043 0.609 0.37–0.98
Significant predictors for  
C. parapsilosis candidemia
  Southern Europe < 0.001 2.754 2.1–3.7
  Infants < 0.001 1.54 1.2–2.0
Only significant predictors are shown in the table (P < 0.05).
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over an extended time period. The observed differences between 
Northern and Southern European countries and trends between 
2005 and 2010 versus 2010 and 2015, point towards potential differ-
ences in infection prevention measures, management of underlying 
conditions, antifungal use, antimicrobial and antifungal stewardship 
policies, and need further exploration. The ward-specific fungal 
epidemiology needs to be addressed in clinical management guide-
lines. Overall, the results of the EUROCANDY study will allow 
development of local, national and European clinical management 
guidelines and to target pediatric antifungal stewardship programs.
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